None of those three is on the 503A bulks list or in Category 1, the only routes that let a 503A pharmacy compound a substance [2]. We found no FDA warning letter to FrontCare as of Oct 24, 2026 [12].
FrontCare is a US cash-pay telehealth service that prescribes compounded GLP-1s, peptides, hormones, hair and skin products after an online intake [4].
Our verdict
AvoidA real company with posted prices, but it sells injectable peptides that no pharmacy may lawfully compound today. We do not link to it.
What checks out
- FDA record
- No warning letter found in FDA's database or in web searches of fda.gov, Oct 24, 2026.
- BBB
- Not checked. bbb.org blocks automated access.
- Best for
- No one, while it sells peptides that cannot be legally compounded.
Is FrontCare legit?
FrontCare is a working business. It runs an online intake, says a doctor reviews each order after checkout, and places a payment hold that is released if you are not approved [6]. It lists compounded GLP-1s, peptides, hormone therapy, testosterone, hair loss, skin care and ED drugs [4]. Its site gives no legal company name or street address, only "FrontCare" and a support email [4] [7].
The problem is what it sells. Its peptide page lists BPC-157, TB-500, CJC-1295/ipamorelin, MOTS-c, DSIP, Selank/Semax, Epithalon and two blends built on BPC-157 and TB-500 [1]. Our peptide FDA status tracker follows each one. Under our rating rule, a live problem on a company's site today is what moves it to Avoid. Selling injectables that no pharmacy may lawfully compound is that kind of problem, so we treat it the same way as live warning-letter claims.
Which FrontCare peptides are legal to compound?
| Product on FrontCare's menu | Can a 503A pharmacy compound it today? | Why | Sources |
|---|---|---|---|
| BPC-157 | No | Not on the 503A bulks list or in Category 1. A July 2026 advisory vote favored listing it, but votes are not binding and FDA has not acted | [1] [2] [14] [9] |
| TB-500 (thymosin beta-4) | No | Same status as BPC-157: favorable but nonbinding July 2026 vote, no FDA action | [1] [2] [14] [9] |
| Glow Stack and Wolverine Stack (BPC-157 and TB-500 blends) | No | Each contains BPC-157 and TB-500 | [1] [2] |
| CJC-1295 / ipamorelin | No | The advisory committee voted against CJC-1295 in December 2024; neither is on the bulks list | [1] [15] [2] |
| MOTS-c | No | Favorable but nonbinding July 2026 vote; FDA has not acted | [1] [14] [2] |
| DSIP | No | The committee voted against it on July 24, 2026 | [1] [16] [2] |
| Selank / Semax | No | Selank is listed as nominated but withdrawn, which does not allow compounding; Semax awaits FDA action | [1] [3] [16] |
| Epithalon | No | Favorable but nonbinding July 2026 vote; FDA has not acted | [1] [16] [2] |
| GHK-Cu (form not stated on the menu) | Injectable: no. Cream or other non-injectable: yes | Non-injectable forms are in Category 1; injectable GHK-Cu may not be compounded | [1] [2] |
| Tesamorelin | No clear legal basis | FDA regulates tesamorelin as a biologic, and biologics are not eligible for 503A compounding | [1] our tesamorelin page |
| NAD+ injection, glutathione injection | Yes, with a prescription | Category 1 | [4] [2] |
| Sermorelin, PT-141 | Not confirmed | We found no clear FDA statement either way | [4] sermorelin |
The interim peptide policy is not in force
HHS and FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House budget office in mid-October 2026. Its text is not public, and it has not been issued [9] [10]. White House review meetings on it are scheduled for Oct 21 to Oct 28, 2026 [11]. Until FDA acts, the July committee votes do not change what a pharmacy may compound [10].
What FrontCare costs
| Plan | 1 month | 3 months | What is included | Source |
|---|---|---|---|---|
| Compounded semaglutide | $229 | $399 ($133 a month) | Any dose; no membership, consult or shipping fee listed | [5] |
| Compounded tirzepatide (with B12) | $349 | $849 ($283 a month) | Any dose; no membership, consult or shipping fee listed | [6] |
We left FrontCare's peptide prices out of this review on purpose. Several of those products cannot be legally compounded, and we do not publish shopping prices for them. Prices for peptides that can be prescribed legally are on our legal peptide price tracker. For approved and compounded GLP-1 prices, see tirzepatide online and semaglutide online.
FDA, BBB and LegitScript check
- FDA warning letters: none to FrontCare in FDA's warning letter database or in fda.gov search results, Oct 24, 2026 [12]. FDA's most recent peptide letters, dated Aug 24, 2026, went to research-peptide sellers, not FrontCare [13]. Our FDA warning letter tracker lists the telehealth letters.
- BBB: not checked. bbb.org blocks automated access.
- LegitScript: not checked. LegitScript's lookup needs an interactive form we could not use.
- Refunds: once an order is approved and charged, FrontCare says it is not refundable. If medical approval is denied, it says you are refunded automatically [7].
Who should look elsewhere
Anyone shopping for BPC-157, TB-500 or the other peptides above should know there is no legal way to buy them for human use in the US today. Our BPC-157 status page explains why. If you want a compounded GLP-1, the company below is rated Clean. If you want a legal peptide such as NAD+, see the price tracker and the full list of reviews.
We earn commissions from some partners, which can affect where they appear on this page. It never changes a verdict. How we make money
Clean-rated alternatives for compounded GLP-1s
- Clean
Good fit for: low-price compounded GLP-1s
PriceSee our bmiMD review- What you get
- Compounded GLP-1 programs
- FDA record
- No live warning letter in our review
- BBB
- F; BBB cites 6 unanswered complaints out of 43, Oct 24, 2026 [17]
Visit bmiMDon the bmiMD website
- Clean
Good fit for: visits and medication in one price
PriceSee our Henry Meds review- What you get
- Visits and medication in one price
- FDA record
- No live warning letter in our review
- BBB
- F; BBB cites 31 unanswered complaints out of 236, mostly billing, cancellation and fulfillment, Oct 24, 2026 [18]
Visit Henry Medson the Henry Meds website
- Clean
Good fit for: compounded, brand and non-GLP-1 options
PriceSee our Found review- What you get
- Compounded semaglutide and tirzepatide, brand GLP-1s and non-GLP-1 options
- FDA record
- No warning letter found in our review
- BBB
- See review
Visit Foundon the Found website
Questions people ask
Is FrontCare legit?
Does FrontCare have an FDA warning letter?
We found none. FDA's warning letter database and fda.gov search showed no letter to FrontCare as of Oct 24, 2026 [12].
How much does FrontCare cost?
Is FrontCare's BPC-157 legal?
Which pharmacy does FrontCare use?
FrontCare does not name one. Its FAQ says it works with licensed 503A compounding pharmacies and that the pharmacy's details appear on the medication label [7].
Can I get a refund from FrontCare?
Only in limited cases. FrontCare says an order is not refundable once it is approved and charged, and that you are refunded automatically if medical approval is denied [7].
What states does FrontCare serve?
FrontCare says it serves all 50 states except Alabama, Mississippi and Alaska, with extra limits on some products [7].
Medical review: pending. A licensed clinician has not yet reviewed this page.
Sources
18 cited
- FrontCare peptides. FrontCare, Oct 24, 2026.
- Bulk drug substances nominated for use in compounding under section 503A (categories document). FDA, May 14, 2026.
- Certain bulk drug substances for use in compounding that may present significant safety risks. FDA, Apr 22, 2026.
- FrontCare home page and product menu. FrontCare, Oct 24, 2026.
- Compounded semaglutide. FrontCare, Oct 24, 2026.
- Compounded tirzepatide. FrontCare, Oct 24, 2026.
- FrontCare FAQs. FrontCare, Oct 24, 2026.
- BPC-157. FrontCare, Oct 24, 2026.
- Peptides at a crossroads: what wellness providers need to know. Holland & Knight, Oct 16, 2026.
- FDA submits interim peptide compounding policy for White House review: what pharmacies should know. Buchanan Ingersoll & Rooney, Oct 16, 2026.
- EO 12866 meetings: Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94). Office of Information and Regulatory Affairs (reginfo.gov), Oct 24, 2026.
- Warning letters database. FDA, Oct 24, 2026.
- FDA balances peptide policy with enforcement against unlawful peptide sellers. Sheppard Mullin (FDA Law Update), Sep 18, 2026.
- Bulk list bound: PCAC backs majority of peptides in two-day public meeting. McDermott Will & Emery, Jul 27, 2026.
- PCAC final summary minutes, Dec 4, 2024. FDA, Dec 4, 2024.
- The peptide wave rolls on: PCAC adds two more bulk drug substances for the 503A list. Hyman, Phelps & McNamara (FDA Law Blog), Jul 24, 2026.
- bmiMD (MEDCCM, Inc.) business profile. Better Business Bureau, Oct 24, 2026.
- Henry Meds business profile. Better Business Bureau, Oct 24, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.